Stake logo

PRAX

PRAXIS PRECISION MEDICINES I

About PRAX

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating genetic insights into the development of therapies for central nervous system (CNS) disorders. Its portfolio of CNS programs is structured by therapeutic focus in three primary franchises, which include Psychiatry, Movement Disorders, and Epilepsy. It has three product candidates, which include PRAX-114, PRAX-944 and PRAX-562. PRAX-114 is an extra synaptic gamma-aminobutyric acid-A (GABAA) receptor preferring positive allosteric modulator (PAM) for the treatment of a range of patients suffering from major depressive disorder (MDD) and perimenopausal depression (PMD). PRAX-944 is a differentiated selective small molecule inhibitor of T-type calcium channels developed for the treatment of Essential Tremor (ET) and Parkinson's Disease(PD). PRAX-114 is developed for the treatment of a range of patients suffering from post-traumatic stress disorder (PTSD).

Buy US stocks in Australia starting with PRAX. Open an account and start investing today!

Market Capitalisation

$212.50M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

466

High today

$4.83

Low today

$4.46

Open price

$0.00

52-week high

$15.32

52-week low

$1.48


PRAX FAQs

One share of PRAXIS PRECISION MEDICINES I is valued at $4.52.

The ticker symbol for PRAXIS PRECISION MEDICINES I is PRAX.

To buy PRAX stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in PRAX

As of 27/01/2023 PRAXIS PRECISION MEDICINES I has a market cap of $213M.

The PRAXIS PRECISION MEDICINES I 52-week high stock price is $15.32.

The PRAXIS PRECISION MEDICINES I 52-week low stock price is $1.48.


Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.